Skip to main content

Table 3 Summary of safety

From: Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications

  Percentages (%)
Elevated aspartate aminotransferase
 Any grade 55.1
 Grade ≥ 3 18.4
Bilirubin elevation
 Any grade 56.0
 Grade ≥ 3 12.0
Hypothyroidism
 Any grade 41.4
 Grade ≥ 3 0
Anemia
 Any grade 26.4
 Grade ≥ 3 3.8
Proteinuria
 Any grade 52.6
 Grade ≥ 3 2.6